Allurion announces plans to optimize muscle mass during glp-1 therapy in combination with the allurion program

Natick, mass.--(business wire)--allurion technologies, inc. (“allurion” or the “company”) (nyse: alur), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the allurion program with glp-1 agonists to improve muscle mass and overall body composition. previous studies in patients undergoing glp-1 therapy have demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost.1 in contrast, in previous.
ALUR Ratings Summary
ALUR Quant Ranking